Pharmacist-led osteoporosis review: perceptions of current practice, care gaps, and implementation challenges
Andrew Sturrock1, Meaghan Grabrovaz2, Laurna Bullock3
1Pharmacy Directorate, Public Services Delivery Scotland, Scotland, UK andrew.sturrock@nhs.scot.
Background:
Adherence to oral bisphosphonates for osteoporosis is poor; the challenges and complexity of follow-up reviews in general practice are implicated as a contributory cause. Clinical pharmacists in general practice are an expanding professional group within the UK NHS workforce and could provide person-centred medicines optimisation interventions.
Aim:
To explore clinician and patient perceptions towards a pharmacist-led osteoporosis review, including identifying current practice, care gaps, and implementation barriers and facilitators.
Design & Setting:
Qualitative interview study with patients, clinical pharmacists, GPs, osteoporosis specialists, and service commissioners.
Method:
Semi-structured interviews were transcribed verbatim and analysed thematically, informed by a normalisation process theory approach.
Results:
In total, 32 participants were interviewed in 22 one-to-one interviews and four small group interviews. Three themes relevant to the design and implementation of a pharmacist-led osteoporosis follow-up review were identified: dissonant views among patients and healthcare professionals about current provision and needs; pharmacists' suitability for, and role in, osteoporosis care and training needs; and contextual issues affecting implementation of a new pharmacist-led osteoporosis review.
Conclusion:
Our study found that current practice with respect to following-up patients initiated on oral bisphosphonate treatment in primary care is variable. Although pharmacists were highlighted as well-placed to conduct osteoporosis reviews, varying views about the need for this were highlighted along with a number of contextual barriers, including lack of financial and policy drivers in primary care, workload challenges, varying pharmacist skills and autonomy, and lack of coordination across the health system.
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Drug Dosing: Geriatric Patients
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...

